IgE-Targeting Allergy Treatment Candidate Gains Market Attention Amid Blockbuster Patent Expiry
Yuhan Corporation is actively expanding its pharmaceutical revenue foundation, anchored by the non-small cell lung cancer treatment Lazertinib, while building high expectations for future technology exports and contract development and ... Read More